Altimmune (NASDAQ:ALT - Get Free Report) is set to release its earnings data before the market opens on Thursday, May 9th. Analysts expect Altimmune to post earnings of ($0.36) per share for the quarter. Individual interested in listening to the company's earnings conference call can do so using this link.
Altimmune (NASDAQ:ALT - Get Free Report) last released its earnings results on Wednesday, March 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.02. Altimmune had a negative return on equity of 44.77% and a negative net margin of 20,780.75%. The firm had revenue of $0.04 million during the quarter. On average, analysts expect Altimmune to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Altimmune Stock Up 1.5 %
NASDAQ ALT traded up $0.11 during trading hours on Friday, reaching $7.30. The company's stock had a trading volume of 2,018,291 shares, compared to its average volume of 5,203,827. Altimmune has a 1 year low of $2.09 and a 1 year high of $14.84. The company has a market capitalization of $517.50 million, a price-to-earnings ratio of -4.42 and a beta of 0.22. The firm's 50-day moving average price is $9.14 and its 200-day moving average price is $7.63.
Analyst Ratings Changes
ALT has been the subject of a number of research reports. HC Wainwright dropped their target price on shares of Altimmune from $15.00 to $12.00 and set a "buy" rating for the company in a research report on Monday, April 1st. Guggenheim lowered Altimmune from a "buy" rating to a "neutral" rating in a research note on Monday. The Goldman Sachs Group initiated coverage on Altimmune in a research note on Wednesday, January 24th. They issued a "neutral" rating and a $13.00 price objective on the stock. Finally, B. Riley reissued a "buy" rating and issued a $20.00 target price on shares of Altimmune in a report on Thursday, March 28th.
Get Our Latest Stock Analysis on Altimmune
Altimmune Company Profile
(
Get Free Report)
Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.
Read More
Before you consider Altimmune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Altimmune wasn't on the list.
While Altimmune currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
